Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-07-26
2005-07-26
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S262000
Reexamination Certificate
active
06921763
ABSTRACT:
The present invention is directed to pyrazolopyrimidine derivatives of formula (I)wherein the substituents are defined herein, which are useful as kinase inhibitors and as such are useful for affecting angiogenesis and diseases and conditions associated with angiogenesis.
REFERENCES:
patent: 4966849 (1990-10-01), Vallee et al.
patent: 5217999 (1993-06-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5330992 (1994-07-01), Eissenstat et al.
patent: 5646128 (1997-07-01), Firestein et al.
patent: 6660744 (2003-12-01), Hirst et al.
patent: 0566226 (1993-10-01), None
patent: 91/15495 (1991-10-01), None
patent: 92/20642 (1992-11-01), None
patent: 92/21660 (1992-12-01), None
patent: 94/03427 (1994-02-01), None
patent: 94/10202 (1994-05-01), None
patent: 94/14808 (1994-07-01), None
patent: 94/18215 (1994-08-01), None
patent: 97/14696 (1997-04-01), None
patent: 97/22596 (1997-06-01), None
patent: 97/34876 (1997-09-01), None
patent: 97/40830 (1997-11-01), None
patent: 97/40831 (1997-11-01), None
patent: 97/42187 (1997-11-01), None
patent: 98/07832 (1998-02-01), None
Chalmers (TiPS vol. 17, pp. 166-172 Apr. 1996).
Lyrer (Schweiz. Med. Wochenschr., vol. 124, #45, 2005-2012 1994).
Frampton (Drugs and Aging 7(6) 480-503 1995).
U.S. Appl. No. 09/663,320, filed Sep. 15, 2000, Hirst et al.
U.S. Appl. No. 09/663,780, filed Sep. 15, 2000, Hirst et al.
U.S. Appl. No. 10/104,140, filed Mar. 22, 2002, Hirst et al.
Schlessinger and Ulrich, “Growth Facotr Signaling by Receptor Tyrosine Kinases”, (1992), Neuron, 9:383-391.
Armstrong, “Treatment of Opportunistic Fungal Infections”, (1993), Clinical Infectious Diseases, 16:1-7.
Stacker, S.A., Vitali, A., Domagala, T., Nice, E., and Wilks, A.F., “Mutations in the V3 Domain of the Cysteine-Knot Motif of Mouse Vascular Endothelial Growth Factor (VEGF) Modulate the Interaction with VEGFR2 (FLK-1) but do not Inhibit Vascular Permeability”, Angiogenesis and Cancer Conference, Amer. Assoc. Cancer Res., Jan. 1998, Orlando, FL.
Williams, “Factors regulating the Expression of Vascular Permeability/Vascular Endothelial Growth Factor by Human Vascular Tissues”, (1997), Diabetelogia, 40: S118-120.
Zindy et al., “Cyclin A is Required in S Phase in Normal Epithelial Cells”, (1992), Biochemical & Biophysical Research Communications, 182:1144-1154.
Buchdunger et al., “Selective Inhibition of the Platelet-Derived Growth Factor Signal Transduction Pathway by a Protein-Tyrosine Kinase Inhibitor of the 2-Phenylaminopyrimidine Class”, (1995), Proceedings of the National Academy of Science USA, 92:2558-2562.
Borthwick et al., “Inhibition of Glycogen Synthase Kinase-3 by Insulin in Cultured Human Skeletal Muscle Myoblasts”, (1995), Biochemical & Biophysical Research Communications, 210(3):738-745.
Badger et al., “Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function”, (1996), The Journal of Pharmacology and Experimental Therapeutics, 279:1453-1461.
Vousden “Interactions of Human Papillomavirus Transforming Proteins with the Products of Tumor Suppressor Genes”, (1993), FASEB Journal, 7:8720879.
Olofsson et al, “Vacsular Endothelial Growth Factor B (VEGF-B) Binds to VEGF Receptor-1 and Regulates Plasminogen Activator Activity in Endothelial Cells”, 1998), Proc. Natl. Acad. Sci. U. S. A., 95(20): 11709-11714.
Shoelson, “SH2 and PTB Domain Interactions in Tyrosine Kinase Signal Transduction”, (1997), Curr. Opin. Chem. Biol., 1(2), 227-234.
Meyer et al, “A Novel Vascular Endothelial Growth Factor Encoded by Orf Virus, VEGF-E, Mediates Angiogenesis Via Signaling Through VEGFR-2 (KDR) but not VEGFR-1 (Flt-1) Receptor Tyrosine Kinases”, (1999), EMBO J., 18(2), 363-374.
“4-Anilinoquinazoline Derivatives”, (1998), Expert Opin. Ther. Pat., 8(4): 475-478.
Witzenbichler et al, “Vascular Endothelial Growth Factor-C (VEGF-C/VEGF-2) Promotes Angiogenesis in the Setting of Tissue Ischemia”, (1998), Am. J. Pathol., 153(2), 381-394.
Lymboussaki et al, “Expression of the Vascular Endothelial Growth Factor C Receptor VEGFR-3 in Lymphatic Endothelium of the Skin and in Vascular Tumors”, (1998), Am. J. Pathol., 153(2): 395-403.
Achen et al, “Vascular Endothelial Growth Factor D (VEGF-D) is a Ligand for the Tyrosine Kinases VEGF Receptor 2 (Flk1) and VEGF Receptor 3 (Flt4)”, (1998), Proc. Natl. Acad. Sci. U. S. A., 95(2), 548-553.
Cowburn, “Peptide Recognition by PTB and PDZ Domains”, (1997), Curr. Opin. Struct. Biol., 7(6), 835-838.
Solomon et al., “Cyclin Activation of p34cdc2”, (1990), Cell, 63:1013-1024.
Oelrichs et al, “NYK/FLK-1: A Putative Receptor Protein Tyrosine Kinase Isolated From E10 Embryonic Neuroepithelium is Expressed in Endothelial Cells of the Developing Embryo”, (1993), Oncogene, 8(1):11-15.
Ferrara et al., “The Biology of Vascular Endothelial Growth Factor”, (1997), Endocrine Reviews, 18(1); 4-25.
Shawver et al., “Receptor Tyrosine Kinases as Targets for Inhibition of Angiogenesis”, (1997), Drug Discovery Today, 2:50-63.
Kohn et al., “Cell Cycle Control and Cancer Chemotherapy”, (1994), Journal of Cellular Biochemistry, 54:440-452.
Powis, “Signalling Pathways as Targets for Anticancer Drug Development”, (1994), Pharmacology & Therapeutics, 62:57-95.
Pines, “Cell Proliferation and Control”, (1992), Current Opinion in Cell Biology, 4:144-148.
Korpelainen and Alitalo, “Signaling Angiogenesis and Lymphangiogenesis”, (1998), Curr. Opin. Cell Biol., 159-164.
Kolch et al., “Regulation of the Expression of the VEGF/VPS and its Receptors: Rile in Tumor Angiogenesis”, (1995), Breast Cancer Research and Treatment, 36: 139-155.
Pines, “Cyclins and Cyclin-dependent Kinases: Take Your Partners”, (1993), Trends in Biochemical Sciences, 18:195-197.
Courtneidge, “Protein Tyrosine Kinases, with Emphasis on the Src Family”, (1994), Seminars in Cancer Biology, 5:236-246.
Bolen, “Nonreceptor Tyrosine Protein Kinases”, (1994), Oncogene, 8:2025-2031.
Klagsburn and D'Amore, “Vascular Endothelial Growth Factor and its Receptors”, (1996), Cytokine & Growth Factor Reviews, 7: 259-270.
Draetta, “Cdc2 Activation: The Interplay of Cyclin Binding and Thr161 Phosphorylation”, (1993), Trends in Cell Biology, 3:287-289.
Solomon et al, “Role of Phosphorylation in p34cdc2 Activation: Identification of an Activating Kinase”, (1992), Mol. Biol. of the Cell, 3:13-27.
Osmani et al., “Parallel Activation of the NIMA and P34cdc2 Cell Cycle-Regulated Protein Kinases is Required to Initiate Mitosis inA. nidulans”, (1991), Cell, 67:283-291.
Brickell, “The p60c-src Family of Protein-Tyrosine Kinases: Structure, Regulation and Function”, (1992), Critical Reviews in Oncogenesis, 3(4):401-406.
Myers et al., “The Synthesis and SAR of New 4-(N-alkyl-N-phenyl0amino-6,7-dimethoxyquinazolines and 4-(N-alkyl-N-phenyl)amino-pyrazolo[3,4-d]pyrimidines, Inhibitors of CSF-1R Tyrosine Kinase Activity”, (1997), Bioorganic & Medicinal Chemistry Letters, 7(4):421-424.
He et al., “The Human Cytomegalovirus UL97 Protein is a Protein Kinase That Autophosphorylates on Serine and Threonines”, (1997), Journal of Virology, 71:405-411.
Yarden and Ullrich, Growth Factor receptor Tyrosine Kinases:, (1988), Ann. Rev. Biochem., 57:433-478.
Shibuya et al., “Nucleotide Seuence and Expression of a Novel Human Receptor-Type Tyrosine Kinase Gene (flt) Closely Related to the fms Family”, (1990), Oncogene, 5:519-524.
Murray and Kirschner, “Cyclin Synthesis Drives the Early Embryonic Cell Cycle”, (1989), Nature, 339:275-280.
Hunter and Pines, “Cy
Arnold Lee D.
Calderwood David
Friedman Michael M.
Hirst Gavin C.
Rafferty Paul
Abbott Laboratories
Berch Mark L.
Habte Kahsay
O'Brien Gayle B.
LandOfFree
Pyrazolopyrimidines as therapeutic agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrazolopyrimidines as therapeutic agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrazolopyrimidines as therapeutic agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3371587